JPWO2021048280A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021048280A5 JPWO2021048280A5 JP2022515966A JP2022515966A JPWO2021048280A5 JP WO2021048280 A5 JPWO2021048280 A5 JP WO2021048280A5 JP 2022515966 A JP2022515966 A JP 2022515966A JP 2022515966 A JP2022515966 A JP 2022515966A JP WO2021048280 A5 JPWO2021048280 A5 JP WO2021048280A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ofatumumab
- composition according
- administered
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025159217A JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789.2 | 2019-09-11 | ||
| EP19196789 | 2019-09-11 | ||
| EP20154736 | 2020-01-30 | ||
| EP20154736.1 | 2020-01-30 | ||
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Division JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548575A JP2022548575A (ja) | 2022-11-21 |
| JP2022548575A5 JP2022548575A5 (https=) | 2023-09-13 |
| JPWO2021048280A5 true JPWO2021048280A5 (https=) | 2023-09-13 |
| JP7794735B2 JP7794735B2 (ja) | 2026-01-06 |
Family
ID=72709332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515966A Active JP7794735B2 (ja) | 2019-09-11 | 2020-09-10 | 切替え療法によるｒｍｓの治療 |
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159217A Pending JP2026016387A (ja) | 2019-09-11 | 2025-09-25 | 切替え療法によるｒｍｓの治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (https=) |
| EP (2) | EP4230655A3 (https=) |
| JP (2) | JP7794735B2 (https=) |
| KR (1) | KR20220062025A (https=) |
| CN (3) | CN118436777A (https=) |
| AU (1) | AU2020344154A1 (https=) |
| CA (1) | CA3150947A1 (https=) |
| DK (1) | DK3864053T3 (https=) |
| ES (1) | ES2957112T3 (https=) |
| FI (1) | FI3864053T3 (https=) |
| IL (1) | IL290619A (https=) |
| LT (1) | LT3864053T (https=) |
| MX (1) | MX2022003010A (https=) |
| SI (1) | SI3864053T1 (https=) |
| WO (1) | WO2021048280A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| MX2022003030A (es) * | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) * | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) * | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| EA201692180A1 (ru) * | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
-
2020
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko active Pending
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201801B2 (en) | Combination therapy for treatment of multiple sclerosis | |
| JP2024102099A5 (https=) | ||
| JP2015187125A5 (https=) | ||
| JP2013521303A5 (https=) | ||
| JP2024129140A5 (https=) | ||
| Kremer et al. | Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial | |
| JP7794735B2 (ja) | 切替え療法によるｒｍｓの治療 | |
| JP2004532869A (ja) | 医薬組成物 | |
| JP2005515214A5 (https=) | ||
| JP2024178420A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| JP7221956B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP5837877B2 (ja) | 静脈内投与イブプロフェンを用いた患者の治療 | |
| JPWO2021048280A5 (https=) | ||
| Zeng et al. | LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study | |
| JPWO2020106927A5 (https=) | ||
| Wroe | Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis | |
| JP2019178177A5 (https=) | ||
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| JP2021121603A (ja) | 多発性硬化症を処置するための併用療法 | |
| WO2024104290A1 (en) | Method for treating multiple sclerosis | |
| JPWO2021202825A5 (https=) | ||
| HK40123216A (zh) | 一种治疗多发性硬化症的方法 | |
| van Riel et al. | Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis | |
| WO2025147499A1 (en) | Lutikizumab for use in a treatment of hidradenitis suppurativa |